Assessing the economic impact of adverse drug effects (Q35154708)

6 August 2017

Assessing the economic impact of adverse drug effects (English)

1 reference

6 August 2017

Rosa Rodríguez-Monguió

series ordinal

1

1 reference

6 August 2017

María José Otero

series ordinal

2

1 reference

6 August 2017

Joan Rovira

series ordinal

3

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

21

1 reference

6 August 2017

9

1 reference

6 August 2017

623-650

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200321090-00002

6 August 2017

0 references

cites work

Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation

1 reference

12 December 2020

1 reference

12 December 2020

Costs of medical injuries in Utah and Colorado

1 reference

12 December 2020

Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations

1 reference

12 December 2020

An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada

1 reference

12 December 2020

Frequency and cost of serious adverse drug reactions in a department of general medicine

1 reference

12 December 2020

1 reference

12 December 2020

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

12 December 2020

Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs?

1 reference

12 December 2020

Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.

1 reference

12 December 2020

1 reference

12 December 2020

COX-1-sparing NSAIDs--is the enthusiasm justified?

1 reference

12 December 2020

Cost of medication-related problems at a university hospital

1 reference

12 December 2020

1 reference

12 December 2020

The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature

1 reference

12 December 2020

Opportunities and responsibilities in pharmaceutical care

1 reference

12 December 2020

Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients

1 reference

12 December 2020

Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis

1 reference

12 December 2020

Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective

1 reference

12 December 2020

A survey on drug-related hospitalization in a community teaching hospital

1 reference

12 December 2020

The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review.

1 reference

12 December 2020

Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs.

1 reference

12 December 2020

Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients--a comment

1 reference

12 December 2020

Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis

1 reference

12 December 2020

Adverse drug reaction surveillance in an emergency room.

1 reference

12 December 2020

Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

1 reference

12 December 2020

Incidence and cost of adverse drug reactions in a French cancer institute.

1 reference

12 December 2020

Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol

1 reference

12 December 2020

Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland

1 reference

12 December 2020

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

12 December 2020

Relationship between medication errors and adverse drug events

1 reference

12 December 2020

Assessing the economic value of a new antidepressant. A willingness-to-pay approach

1 reference

12 December 2020

Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres

1 reference

12 December 2020

Indirect drug-related costs

1 reference

12 December 2020

1 reference

12 December 2020

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group

1 reference

12 December 2020

[Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects]

1 reference

12 December 2020

The health care cost of drug-related morbidity and mortality in nursing facilities

1 reference

12 December 2020

Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units

1 reference

12 December 2020

The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly.

1 reference

12 December 2020

Nonsteroidal anti-inflammatory drug prescribing: past, present, and future

1 reference

12 December 2020

Putting adverse drug events into perspective

1 reference

12 December 2020

1 reference

12 December 2020

A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis

1 reference

12 December 2020

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

12 December 2020

Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury

1 reference

12 December 2020

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

12 December 2020

Drug-Related Morbidity and Mortality

1 reference

12 December 2020

Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability

1 reference

12 December 2020

Practical approach to determining costs and frequency of adverse drug events in a health care network

1 reference

12 December 2020

1 reference

12 December 2020

Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

1 reference

12 December 2020

[Preventable adverse drug effects at an emergency department]

1 reference

12 December 2020

The cost of rheumatoid arthritis

1 reference

12 December 2020

Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group

1 reference

12 December 2020

Cost of hospitalizations for adverse drug effects

1 reference

12 December 2020

10.2165/00019053-200321090-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

1032926564

0 references

Fatcat ID

release_yhn2erdyi5aqzdrihmd5enrajm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yhn2erdyi5aqzdrihmd5enrajm

24 November 2022

mapped directly with Wikidata item

1 reference